NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 113.60 |
| Open | 113.86 |
| Bid | 114.66 x 800 |
| Ask | 114.80 x 900 |
| Day's Range | 112.25 - 115.21 |
| 52 Week Range | 50.88 - 120.90 |
| Volume | 357,286 |
| Avg. Volume | 662,321 |
| Market Cap | 10.374B |
| Beta | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | Oct 30, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 130.20 |
- PR Newswire•2 days ago
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders
SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and data analyses from a Phase III study on opicapone, an investigational treatment for Parkinson's disease.
Markit•3 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- GlobeNewswire•4 days ago
Report: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy ...
- Benzinga•10 days ago
4 Reasons Behind Stifel's Neurocrine Bull Thesis
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), which already has two strong drugs in the market in the form of Ingrezza and the recently approved elagolix, has a promising pipeline ahead, according to Stifel. ...
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of NBIX earnings conference call or presentation 31-Jul-18 8:30pm GMT
Q2 2018 Neurocrine Biosciences Inc Earnings Call
Market Realist•11 days agoAnalysts Are Mostly Positive on Neurocrine Biosciences in August
In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.
Market Realist•11 days agoHow Neurocrine Biosciences Performed in the Second Quarter
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
- Benzinga•15 days ago
The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...
- ACCESSWIRE•15 days ago
Today’s Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Strong second quarter results and sales of Ingrezza sent shares of Neurocrine Biosciences higher on Wednesday to a new high and a market cap of over $10 billion. Shares of Rxi Pharmaceuticals also soared on positive study results. RXi Pharmaceuticals Corporation shares closed up 20.95% on Wednesday on nearly 13.2 million shares traded.
- Motley Fool•16 days ago
Here's Why Neurocrine Biosciences Stock Rose as Much as 14.3% Today
The company reported second-quarter 2018 results.
- MarketWatch•16 days ago
Neurocrine stock rises 11% after Q2 revenue beat
Neurocrine Biosciences Inc. (NBIX) shares rose more than 11% in heavy Wednesday morning trade after the company reported a second-quarter revenue beat and a smaller-than-expected profit loss. The revenue beat was made possible by what Chief Executive Kevin Gorman described as the "continued adoption of Ingrezza by physicians and patients," referring to its drug for the rare condition tardive dyskinesia, whichcame to market last year.
- Associated Press•17 days ago
Neurocrine: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- PR Newswire•17 days ago
Neurocrine Biosciences Reports Second Quarter 2018 Financial Results
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx ORILISSA™ (elagolix), the First FDA-Approved Oral Treatment for Moderate to Severe Endometriosis ...
- ACCESSWIRE•17 days ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern ...
Markit•17 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Reuters•24 days ago
AbbVie prices new endometriosis drug at $10,000 a year
Drugmaker AbbVie Inc priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday. Orilissa was approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. The company, along with partner Neurocrine Biosciences Inc, released positive Phase III results for the drug for treatment of uterine fibroids.
- PR Newswire•24 days ago
AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.1,2 The FDA approved ORILISSA under priority review. ORILISSA represents the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade and is expected to be available in U.S. retail pharmacies in early August 2018.
Market Realist•last monthWhy Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
- PR Newswire•last month
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, July 31 SAN DIEGO , July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial ...
Market Realist•last monthWhy Analysts are Mostly Positive On Acceleron Pharma
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- ACCESSWIRE•last month
Free Technical Reports on Novavax and Three Additional Biotech Equities
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Motley Fool•2 months ago
3 Biotech Stocks With Major Potential Catalysts in July
FDA approvals next month could be huge for these biotech stocks.
- TheStreet.com•2 months ago
5 Stocks That Are Screaming Buys Right Now
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
